Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition

Journal of Clinical Pharmacology

Volumn 44, Issue 8, 2004, Pages 861-865

  Lehmann, David ^a,b   Nelsen, Jamie ^a   Ramanath, Vijay ^a   Newman, Nancy ^a   Duggan, David ^a   Smith, Adrienne ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

CYP isoform inhibition; Depression; Estrogen receptor positive breast cancer; Selective serotonin reuptake inhibitors; Tamoxifen

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; AMLODIPINE; ANTIESTROGEN; ATORVASTATIN; CODEINE; CYTOCHROME P450 2C9; CYTOCHROME P450 2C9 INHIBITOR; CYTOCHROME P450 2D6; CYTOCHROME P450 2D6 INHIBITOR; CYTOCHROME P450 3A; CYTOCHROME P450 3A INHIBITOR; DIAZEPAM; DILTIAZEM; ENZYME INHIBITOR; ESTROGEN RECEPTOR; FELODIPINE; FLUOXETINE; IBUPROFEN; IMIPRAMINE; LOSARTAN; METOPROLOL; MEVINOLIN; NAPROXEN; NEFAZODONE; NIFEDIPINE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATTENUATION; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DISEASE CLASSIFICATION; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; FEMALE; HUMAN; INHIBITION KINETICS; LONG TERM CARE; NULL ALLELE; PREVALENCE; STATISTICAL SIGNIFICANCE;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HUMANS; ISOENZYMES; SEROTONIN UPTAKE INHIBITORS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 3242780717     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004266618     Document Type: Article

References (11)

1. Early Breast Cancer Trials' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930-942.
2. Early Breast Cancer Trials' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-1467.
3. Jordan VC, Collins MM, Rowsby L, Prestwich G: A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 1977;75:305-316.
4. Crewe HK, Ellis SW, Lennard S, Tucker GT: Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 1997;53:171-178.
5. Flockhart DA: Drug interactions: Defining genetics influences on pharmacological responses. Retrieved from www.drug-interactions. com
6. Narrow WE, Rae DS, Robins LN, Regier DA: Revised prevalence estimates of mental disorders in the United States. Arch Gen Psychiatry 2002;59:115-123.
7. McDaniel JS, Musselman DL, Porter MR, Reed DA, Nemeroff CB: Depression in patients with cancer: diagnosis, biology, and treatment. Arch Gen Psychiatry 1995;52:89-99.
8. Friedman R: Watch for depression in long-term tamoxifen use. Medscape Medical News, 2003. Retrieved from www.medscape. com/viewarticle/455908
9. Greenberg RS, Daniels SR, Flanders WD, Eley JW, Boring JR: Medical Epidemiology. Norwalk, CT: Appleton & Lange, 1993.
10. Breslow NE, Day NE: Statistical Methods in Cancer Research: Vol. 1. The Analysis of Case-Control Studies. Washington, DC: IARC Scientific Publications, 1980.
11. MacCallum J, Cummings J, Dixon JM, Miller WR: Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours. Br J Cancer 2000;82:1629-1635.